Novartis Showcases Rhapsido Data at EAACI 2026
BASEL, Switzerland, June 8, 2026 Novartis announced the presentation of data from 10 scientific abstracts at the European Academy...
chronic spontaneous urticaria
Advertisement
Kashiv BioSciences Moves Closer to Launching XOLAIR Biosimilar in Canada
PISCATAWAY, N.J., June 4, 2026 Kashiv BioSciences has announced a significant regulatory milestone with the validation and acceptance by...
Nurix Shows Promising CSU Data for Bexobrutideg
BRISBANE, Calif., May 14, 2026 Nurix Therapeutics presented new preclinical and Phase 1 translational data at the Society for...
Regeneron & Sanofi Secure FDA Approval for Dupixent in Pediatric CSU
Tarrytown, New York, USA & Paris, France – April 22, 2026 In a significant advancement for pediatric immunology and...
Regeneron Dupixent EU Approval Expands Pediatric CSU Care
TARRYTOWN, N.Y. and PARIS, April 13, 2026 Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Commission has approved...
Advertisements
CuraTeQ Reports Positive Phase 3 Results for BP11 Biosimilar
Hyderabad, India, April 7, 2026 Phase 3 Trial Confirms Biosimilar Equivalence In a significant milestone for biosimilar drug development,...
Celldex Barzolvolimab Shows Strong Phase 2 Urticaria Data
Hampton, N.J., USA | March 27, 2026 Celldex Therapeutics reported compelling results from Phase 2 clinical trials of barzolvolimab,...
InflaRx Secures INN “Izicopan” for Oral C5aR Inhibitor INF904
JENA, Germany, December 11, 2025 — InflaRx N.V. announced that the World Health Organization (WHO) has granted the International...
Valneva Reports Strong Phase 2 Data for VLA15 Vaccine
SAINT-HERBLAIN, FRANCE — November 26, 2025. Valneva has announced positive final Phase 2 results for its Lyme disease vaccine...
EU Approves Dupixent as First Targeted CSU Therapy
TARRYTOWN, N.Y. & PARIS — November 25, 2025. The European Commission has granted landmark approval for Dupixent® (dupilumab) as...
Advertisement
